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clinical constraints) and overdose comparable to the nominal 
case. Doses to organs at risk were similar for the three plans 
in both patients. 
 
 
Conclusion: The proposed strategies achieved robust plans in 
term of target coverage without increasing the dose to the 
CTV nor to the organs at risk. Full robust optimization gives 
better results than the mixed strategy, but the latter can be 
useful in cases where a MC engine is not available or too 
computationally intensive for beamlets calculation.  
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Purpose or Objective: The aim of the study was to develop a 
fully automated treatment planning procedure to generate 
VMAT plans for stage III/IV non-small cell lung cancer (NSCLC) 
patients, treated with curative intent, and to compare them 
with manually generated plans. 
 
Material and Methods: Based on treatment plans of 7 
previously treated patients, the clinical protocol, and 
physician’s treatment goals and priorities, our in-house 
developed system for fully automated, multi-criterial plan 
generation was configured to generate VMAT plans for 
advanced stage NSCLC patients without human interaction. 
For 41 independent patients, treated between January and 
August 2015, automatic plan generation was then compared 
with manual plan generation, as performed in clinical 
routine. Differences in PTV coverage, dose conformality R50 
(the ratio between the total volume receiving at least 50% of 
the prescribed dose and the PTV volume) and sparing of 
organs at risk were quantified, and their statistical 
significance was assessed using a Wilcoxon test. 
 
Results: For 35 out of 41 patients (85%), the automatically 
generated VMAT plans were clinically acceptable as judged 
by two physicians. Compared to the manually generated 
plans, they considered the quality of automatically generated 
plans superior for at least 67% of patients, due to a 
combination of better PTV coverage, dose conformality and 
sparing of lungs, heart and oesophagus (positive values in 
figure). For the other acceptable plans plan quality was 
considered equivalent. On average, PTV coverage (V95) was 
improved by 1.1 % (p<0.001), the near-minimum dose in the 
PTV (D99) by 0.55 Gy (p=0.006) and the R50 by 12.4% 
(p<0.001). The mean lung dose was reduced by 0.86 Gy 
(4.6%, p<0.001), and the V20 of the lungs by 1.3 % (p=0.001). 
For some patients it was possible to improve PTV V95 by 
3.8%, D99 by 3.3 Gy, to reduce mean lung dose by 3.0 Gy and 
V20 by 6.2%. All plans fulfilled the planning constraints for 
the spinal cord, heart and plexus. 
For the 6 automated VMAT plans that were initially not 
acceptable, it took a dosimetrist less than 10 minutes hands-
on time to manually fine-tune the VMAT plan in our TPS to 
make it acceptable. In contrast, to generate a VMAT plan 
from scratch 3-4 hours were required.  
For 5 out of 10 patients with a PTV prescription dose of less 
than 66 Gy in the manual plan, we were able to escalate the 
tumour dose using automated planning. For two patients dose 
escalation from 60 Gy to 66 Gy was possible, for other 
patients from 60.5 Gy to 66 Gy, 45 Gy to 57.75 Gy, and 55 Gy 
to 60.5 Gy, respectively. 
 
 
 
Conclusion: Using our fully automated treatment planning 
procedure, clinically deliverable, high quality VMAT plans for 
advanced stage NSCLC patients may be generated without 
human interaction for the far majority of patients. When 
manual adjustments were required, they took very little 
hands-on time only. With automated planning, a higher 
tumour dose could be achieved for a subgroup of patients. 
Clinical introduction has been started. 
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Purpose or Objective: In stereotactic body radiation 
therapy, high accuracy is required to deliver high fraction 
doses with steep dose gradients. Non-coplanar beam setups 
may improve plan quality. This can be realized with a robotic 
CyberKnife (CK, Accuray Inc, Sunnyvale, USA). Due to its 
tumor tracking features, CTV-PTV margins may be reduced 
compared to linac treatment. In previous works we have built 
and validated a system for fully automated, multi-criterial 
VMAT plan generation (iCycle/Monaco). Recently, we have 
extended the system with an option for fully automated plan 
generation for the CK (iCycle/Multiplan). In this study we 
have used fully automated plan generation for un-biased 
comparison of non-coplanar CK with coplanar VMAT at a 
linac, for prostate SBRT. 
 
Material and Methods: Our in-house iCycle system was first 
coupled to the Multiplan TPS that comes with the CK 
treatment unit. The iCycle/Multiplan and iCyle/Monaco 
systems were then configured for automated prostate SBRT 
plan generation for CK and linac-VMAT, respectively. Plans 
were then generated for 10 prostate SBRT patients, 
delivering 38 Gy in 4 fractions. Three clinically deliverable 
